Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Thoracic Oncology

Topics

Medicine

Cancer Oncology

Epidemiology

Internal Medicine

Surgery

Show all topics

DOI

10.1016/j.jtho.2019.12.109

License

publisher-specific-oa